{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-244709","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.779058+00:00","generated_at":"2026-06-29T13:44:17.790257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands","bullets":["Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.","Cash, cash equivalents and marketable securities $806.6M as of June 30.","R&D expenses $14.0M, up from $7.3M, on higher clinical and preclinical costs.","Phase 1/2 of NUV-422 expanded to glioblastoma, breast, and prostate cancers; Phase 1 data expected 2022.","Appointed David C. Hanley as Chief Technical Operations Officer in June 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-244709","json":"https://secwatch.observer/filing/0001193125-21-244709.json","markdown":"https://secwatch.observer/filing/0001193125-21-244709.md","text":"https://secwatch.observer/filing/0001193125-21-244709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/0001193125-21-244709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/d212585d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:44:17.790257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}